Michael Davidson, MD

JCP
Add-on Pramipexole for Schizophrenia
Original Research

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
Linda Levi, Daisy Zamora, Igor Nastas, et al
JCP
Original Research

May 15, 2018

The currently available dopamine-blocking antipsychotics haven' t been of much help with cognitive deficits in schizophrenia. This post hoc analysis of an RCT examines whether MIN-101, which combines sigma-2...
Richard S. E. Keefe, Philip D. Harvey, Anzalee Khan, et al
JCP
Original Research

September 15, 2012

Yona Geffen, Richard Keefe, Jonathan Rabinowitz, et al
JCP
Original Research

June 15, 2012

Mark Weiser, Uriel Heresco-Levy, Michael Davidson, et al
JCP
Original Research

November 1, 2004

Mark Weiser, Hilla Knobler, Gad Lubin, et al
JCP
Original Research

October 15, 2004

Jonathan Rabinowitz, Ira R. Katz, Peter Paul De Deyn, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al
JCP
Article

May 1, 2004

Daniel E. Casey, Dan W. Haupt, John W. Newcomer, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe